抗抑郁药物的研究进展

被引:63
作者
李玥
贺敏
张磊阳
裘福荣
陈文文
吴雨
杨蒋伟
蒋健
机构
[1] 上海中医药大学附属曙光医院临床药理科
关键词
抑郁症; 抗抑郁药物; 单胺类神经递质; 速效抗抑郁药物;
D O I
暂无
中图分类号
R749.4 [情感性精神病];
学科分类号
100204 [神经病学];
摘要
目的:对临床上使用的及临床试验中的抗抑郁药物进行分析和总结,拟为今后新型抗抑郁药物的研发提供参考。方法:通过查阅近年的文献,将抗抑郁药物按照机制进行归纳和整理。结果:从第一代的三环类、单胺氧化酶抑制剂类抗抑郁药物,到第二代的基于单胺类神经递质及相应受体所研发的药物,之前的研发集中在调节单胺类神经递质的摄取和释放方面。而随着氯胺酮等快速起效的抗抑郁药物的发现,新的靶点,比如谷氨酸神经递质及相关通路成为研究的热点。结论:抗抑郁药物的发展仍会遵循着单胺类的策略,但是靶向谷氨酸神经递质系统的药物及联合用药是新的发展趋势。
引用
收藏
页码:8 / 13
页数:6
相关论文
共 22 条
[1]
Treating comorbid anxiety and depression: Psychosocial and pharmacological approaches [J].
Coplan, Jeremy D. ;
Aaronson, Cindy J. ;
Panthangi, Venkatesh ;
Kim, Younsuk .
WORLD JOURNAL OF PSYCHIATRY, 2015, 5 (04) :366-378
[2]
常用抗抑郁药物的比较及合理应用 [J].
邹羽真 ;
史亦丽 .
临床药物治疗杂志, 2012, 10 (06) :48-51
[3]
抗抑郁药临床治疗的选择 [J].
季建林 .
临床药物治疗杂志, 2012, 10 (02) :23-26
[4]
KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS [J].
Abdallah, Chadi G. ;
Adams, Thomas G. ;
Kelmendi, Benjamin ;
Esterlis, Irina ;
Sanacora, Gerard ;
Krystal, John H. .
DEPRESSION AND ANXIETY, 2016, 33 (08) :689-697
[5]
GABA interneurons mediate the rapid antidepressant-like effects of scopolamine [J].
Wohleb, Eric S. ;
Wu, Min ;
Gerhard, Danielle M. ;
Taylor, Seth R. ;
Picciotto, Marina R. ;
Alreja, Meenakshi ;
Duman, Ronald S. .
JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (07) :2482-2494
[6]
In Utero Exposure to Selective Serotonin Reuptake Inhibitors and Risk for Autism Spectrum Disorder [J].
Gidaya, Nicole B. ;
Lee, Brian K. ;
Burstyn, Igor ;
Yudell, Michael ;
Mortensen, Erik L. ;
Newschaffer, Craig J. .
JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, 2014, 44 (10) :2558-2567
[7]
Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss.[J].Sonja K. Billes;Puspha Sinnayah;Michael A. Cowley.Pharmacological Research.2014,
[8]
Mechanism of action of the SPARI vilazodone: serotonin 1A partial agonist and reuptake inhibitor [J].
Stahl, Stephen M. .
CNS SPECTRUMS, 2014, 19 (02) :105-109
[9]
The role of serotonin in memory: interactions with neurotransmitters and downstream signaling [J].
Seyedabadi, Mohammad ;
Fakhfouri, Gohar ;
Ramezani, Vahid ;
Mehr, Shahram Ejtemaei ;
Rahimian, Reza .
EXPERIMENTAL BRAIN RESEARCH, 2014, 232 (03) :723-738
[10]
Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat; number needed to harm and likelihood to be helped or harmed?.[J].L. Citrome.Int J Clin Pract.2014, 1